Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

Affiliation auteurs!!!! Error affiliation !!!!
TitrePredictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
Type de publicationJournal Article
Year of Publication2020
AuteursAparicio T, Bennouna J, Le Malicot K, Boige V, Taieb J, Bouche O, Phelip J-M, Francois E, Borel C, Faroux R, Dahan L, Bachet J-B, Egreteau J, Kaminsky M-C, Gornet J-M, Cojocarasu O, Gasmi M, Guerin-Meyer V, Lepage C, Ghiringhelli F, Collaborator PRODIGEInvestigat
JournalBRITISH JOURNAL OF CANCER
Volume122
Pagination957-962
Date PublishedMAR
Type of ArticleArticle
ISSN0007-0920
Résumé

{Background Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying patients who may have a chemotherapy-free interval (CFI) after IC are two major challenges. Methods A logistic model was used to identify factors associated with early progression during IC and with short duration of the first CFI in 488 patients enrolled in the PRODIGE 9 trial. Independent factors were defined with a threshold 0.10. Results In multivariate analysis, baseline leukocytes >10 x 10(9)/L (OR = 1.98 [1.02-3.8]
DOI10.1038/s41416-020-0735-8